{"transactions":[{"id":4622958,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Explanation of Responses"}}],"security":"Stock Option","published_at":"2026-09-18T23:45:38.000Z","date":"2026-09-16","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests in monthly increments over a period of one year from the grant date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and R. Thorvald Nagel, who serves on the Issuer's board of directors and as a Principal of Partners, pursuant to which Mr. Nagel is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Nagel disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":25370,"derivative":{"exercise_price":10.12,"expiration_date":"2036-09-16","underlying":"Common Stock, $0.0001 par value","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0000921895-26-002590","document":"form407422010_09182026.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526002590/form407422010_09182026.xml","form_type":"4"}},{"id":691787,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":24976,"kind":"person","name":"Ridloff Elena","position":1,"cik":"0001772518","reported_name":"Ridloff Elena","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-08-10T23:00:13.000Z","date":"2026-08-06","kind":"grant","planned":false,"acquired":true,"shares":50740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest in monthly increments over a period of three years from the grant date."}],"balance_after":50740,"derivative":{"exercise_price":14.54,"expiration_date":"2036-08-06","underlying":"Common Stock","underlying_shares":50740},"source":{"system":"sec-edgar","filing":"0001193805-26-001069","document":"e665686_4-ridloff.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526001069/e665686_4-ridloff.xml","form_type":"4"}},{"id":713489,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31661,"kind":"person","name":"Rudick Richard Alan","position":1,"cik":"0001975263","reported_name":"Rudick Richard Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-07-07T20:06:38.000Z","date":"2026-07-05","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":25370,"derivative":{"exercise_price":14.8,"expiration_date":"2036-07-05","underlying":"Common Stock","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0001193805-26-000931","document":"e665634_4-rudick.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000931/e665634_4-rudick.xml","form_type":"4"}},{"id":713488,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31660,"kind":"person","name":"PHILLIPS BARCLAY A","position":1,"cik":"0001265801","reported_name":"PHILLIPS BARCLAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-07-07T20:06:09.000Z","date":"2026-07-05","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":25370,"derivative":{"exercise_price":14.8,"expiration_date":"2036-07-05","underlying":"Common Stock","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0001193805-26-000930","document":"e665633_4-phillips.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000930/e665633_4-phillips.xml","form_type":"4"}},{"id":713486,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31659,"kind":"person","name":"Neermann Joerg","position":1,"cik":"0001773900","reported_name":"Neermann Joerg","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-07-07T20:05:37.000Z","date":"2026-07-05","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":25370,"derivative":{"exercise_price":14.8,"expiration_date":"2036-07-05","underlying":"Common Stock","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0001193805-26-000929","document":"e665632_4-jorg.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000929/e665632_4-jorg.xml","form_type":"4"}},{"id":713487,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":30285,"kind":"person","name":"Congleton Jon","position":1,"cik":"0001644975","reported_name":"Congleton Jon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-07-07T20:05:10.000Z","date":"2026-07-05","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":25370,"derivative":{"exercise_price":14.8,"expiration_date":"2036-07-05","underlying":"Common Stock","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0001193805-26-000928","document":"e665631_4-congleton.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000928/e665631_4-congleton.xml","form_type":"4"}},{"id":713794,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31759,"kind":"person","name":"Skerjanec Simona","position":1,"cik":"0002022163","reported_name":"Skerjanec Simona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-07-07T16:07:12.000Z","date":"2026-07-05","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":25370,"derivative":{"exercise_price":14.8,"expiration_date":"2036-07-05","underlying":"Common Stock","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0001193805-26-000932","document":"e665635_4-skerjanec.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022163/000119380526000932/e665635_4-skerjanec.xml","form_type":"4"}},{"id":723881,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":30285,"kind":"person","name":"Congleton Jon","position":1,"cik":"0001644975","reported_name":"Congleton Jon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-29T20:34:34.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":50740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in thirty-six (36) equal installments on each monthly anniversary of March 27, 2026."}],"balance_after":50740,"derivative":{"exercise_price":10.9,"expiration_date":"2036-03-27","underlying":"Common Stock","underlying_shares":50740},"source":{"system":"sec-edgar","filing":"0001193805-26-000892","document":"e665612_4-congleton.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000892/e665612_4-congleton.xml","form_type":"4"}},{"id":724371,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31759,"kind":"person","name":"Skerjanec Simona","position":1,"cik":"0002022163","reported_name":"Skerjanec Simona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-29T20:34:08.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested as of March 27, 2026."}],"balance_after":25370,"derivative":{"exercise_price":10.9,"expiration_date":"2036-03-27","underlying":"Common Stock","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0001193805-26-000891","document":"e665611_4-skerjanec.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022163/000119380526000891/e665611_4-skerjanec.xml","form_type":"4"}},{"id":723879,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31661,"kind":"person","name":"Rudick Richard Alan","position":1,"cik":"0001975263","reported_name":"Rudick Richard Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-29T20:33:45.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested as of March 27, 2026."}],"balance_after":25370,"derivative":{"exercise_price":10.9,"expiration_date":"2036-03-27","underlying":"Common Stock","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0001193805-26-000890","document":"e665610_4-rudick.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000890/e665610_4-rudick.xml","form_type":"4"}},{"id":723878,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":17364,"kind":"person","name":"HOWSON TAMAR D","position":1,"cik":"0001202286","reported_name":"HOWSON TAMAR D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-29T20:33:14.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested as of March 27, 2026."}],"balance_after":25370,"derivative":{"exercise_price":10.9,"expiration_date":"2036-03-27","underlying":"Common Stock","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0001193805-26-000889","document":"e665609_4-howson.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000889/e665609_4-howson.xml","form_type":"4"}},{"id":723877,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31659,"kind":"person","name":"Neermann Joerg","position":1,"cik":"0001773900","reported_name":"Neermann Joerg","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-29T20:32:51.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested as of March 27, 2026."}],"balance_after":25370,"derivative":{"exercise_price":10.9,"expiration_date":"2036-03-27","underlying":"Common Stock","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0001193805-26-000888","document":"e665608_4-jorg.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000888/e665608_4-jorg.xml","form_type":"4"}},{"id":723876,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31660,"kind":"person","name":"PHILLIPS BARCLAY A","position":1,"cik":"0001265801","reported_name":"PHILLIPS BARCLAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-29T20:32:22.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":25370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock conditionally approved by the Board of Directors on March 27, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested as of March 27, 2026."}],"balance_after":25370,"derivative":{"exercise_price":10.9,"expiration_date":"2036-03-27","underlying":"Common Stock","underlying_shares":25370},"source":{"system":"sec-edgar","filing":"0001193805-26-000887","document":"e665607_4-phillips.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000887/e665607_4-phillips.xml","form_type":"4"}},{"id":723875,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option","published_at":"2026-06-29T20:31:55.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":253000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock conditionally approved by the Board of Directors, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months."}],"balance_after":253000,"derivative":{"exercise_price":11.6,"expiration_date":"2036-04-02","underlying":"Common Stock","underlying_shares":253000},"source":{"system":"sec-edgar","filing":"0001193805-26-000886","document":"e665606_4-jason.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000886/e665606_4-jason.xml","form_type":"4"}},{"id":723874,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34788,"kind":"person","name":"Whaley Glenn","position":1,"cik":"0001724623","reported_name":"Whaley Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2026-06-29T20:31:25.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock conditionally approved by the Board of Directors, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months."}],"balance_after":120000,"derivative":{"exercise_price":11.6,"expiration_date":"2036-04-02","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001193805-26-000885","document":"e665605_4-whaley.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000885/e665605_4-whaley.xml","form_type":"4"}},{"id":723873,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34787,"kind":"person","name":"Vitt Daniel","position":1,"cik":"0001773673","reported_name":"Vitt Daniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-29T20:31:00.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":445000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock conditionally approved by the Board of Directors, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months."}],"balance_after":445000,"derivative":{"exercise_price":11.6,"expiration_date":"2036-04-02","underlying":"Common Stock","underlying_shares":445000},"source":{"system":"sec-edgar","filing":"0001193805-26-000884","document":"e665604_4-vitt.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000884/e665604_4-vitt.xml","form_type":"4"}},{"id":723868,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":15604,"kind":"person","name":"BONNEY MICHAEL W","position":1,"cik":"0001219016","reported_name":"BONNEY MICHAEL W","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-29T20:30:32.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents options to purchase shares of common stock conditionally approved by the Board of Directors on May 15, 2026, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest in thirty-six (36) equal installments on each monthly anniversary of May 15, 2026."}],"balance_after":100000,"derivative":{"exercise_price":12.08,"expiration_date":"2036-05-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193805-26-000883","document":"e665603_4-bonney.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000883/e665603_4-bonney.xml","form_type":"4"}},{"id":756857,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":42759,"kind":"person","name":"Lundgren Erik","position":1,"cik":"0002137540","reported_name":"Lundgren Erik","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option","published_at":"2026-06-01T21:57:14.000Z","date":"2026-05-22","kind":"grant","planned":false,"acquired":true,"shares":1000000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options disclosed on this Form 4 are time vested; twenty-five percent (25%) of the shares underlying the options awarded to the Reporting Person will vest on May 22, 2027, and the remaining seventy-five percent (75%) vesting on a monthly basis in thirty-six (36) equal installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date. The Reporting Person became a director and a Section 16 insider on June 1, 2026."}],"balance_after":1000000,"derivative":{"exercise_price":13.05,"expiration_date":"2036-05-22","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0001193805-26-000731","document":"e665512_4-lundgren.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000731/e665512_4-lundgren.xml","form_type":"4"}},{"id":797890,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":35596,"kind":"person","name":"Panzara Michael A.","position":1,"cik":"0001679039","reported_name":"Panzara Michael A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2026-04-29T11:14:41.000Z","date":"2026-04-24","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options disclosed on this Form 4 are time vested; 50 percent of the shares underlying the options awarded to the Reporting Person will vest on April 24, 2027, and 50 percent of them will vest in 24 equal monthly installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date."}],"balance_after":300000,"derivative":{"exercise_price":8.8,"expiration_date":"2036-04-24","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193805-26-000529","document":"e665406_4-panzara.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380526000529/e665406_4-panzara.xml","form_type":"4"}},{"id":1084621,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34788,"kind":"person","name":"Whaley Glenn","position":1,"cik":"0001724623","reported_name":"Whaley Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:30.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":280000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001193805-25-001069","document":"e664709_4-whaley.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001069/e664709_4-whaley.xml","form_type":"4"}},{"id":1084620,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34788,"kind":"person","name":"Whaley Glenn","position":1,"cik":"0001724623","reported_name":"Whaley Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:30.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the \"January 2024 Offering\")."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":280000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001193805-25-001069","document":"e664709_4-whaley.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001069/e664709_4-whaley.xml","form_type":"4"}},{"id":1084619,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34788,"kind":"person","name":"Whaley Glenn","position":1,"cik":"0001724623","reported_name":"Whaley Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:30.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":560000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":560000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":560000},"source":{"system":"sec-edgar","filing":"0001193805-25-001069","document":"e664709_4-whaley.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001069/e664709_4-whaley.xml","form_type":"4"}},{"id":1084618,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34788,"kind":"person","name":"Whaley Glenn","position":1,"cik":"0001724623","reported_name":"Whaley Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:30.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":560000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":560000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":560000},"source":{"system":"sec-edgar","filing":"0001193805-25-001069","document":"e664709_4-whaley.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001069/e664709_4-whaley.xml","form_type":"4"}},{"id":1084617,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34788,"kind":"person","name":"Whaley Glenn","position":1,"cik":"0001724623","reported_name":"Whaley Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:30.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":280000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":280000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":280000},"source":{"system":"sec-edgar","filing":"0001193805-25-001069","document":"e664709_4-whaley.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001069/e664709_4-whaley.xml","form_type":"4"}},{"id":1084616,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:15.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":315000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0001193805-25-001068","document":"e664708_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001068/e664708_4-duane.xml","form_type":"4"}},{"id":1084615,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:15.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the \"January 2024 Offering\")."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":315000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0001193805-25-001068","document":"e664708_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001068/e664708_4-duane.xml","form_type":"4"}},{"id":1084614,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:15.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":630000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":630000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":630000},"source":{"system":"sec-edgar","filing":"0001193805-25-001068","document":"e664708_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001068/e664708_4-duane.xml","form_type":"4"}},{"id":1084613,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:15.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":630000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":630000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":630000},"source":{"system":"sec-edgar","filing":"0001193805-25-001068","document":"e664708_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001068/e664708_4-duane.xml","form_type":"4"}},{"id":1084612,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:06:15.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":315000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0001193805-25-001068","document":"e664708_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001068/e664708_4-duane.xml","form_type":"4"}},{"id":1084611,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34787,"kind":"person","name":"Vitt Daniel","position":1,"cik":"0001773673","reported_name":"Vitt Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:05:56.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":860000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":860000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":860000},"source":{"system":"sec-edgar","filing":"0001193805-25-001067","document":"e664707_4-vitt.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001067/e664707_4-vitt.xml","form_type":"4"}},{"id":1084610,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34787,"kind":"person","name":"Vitt Daniel","position":1,"cik":"0001773673","reported_name":"Vitt Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:05:56.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":860000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the \"January 2024 Offering\")."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":860000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":860000},"source":{"system":"sec-edgar","filing":"0001193805-25-001067","document":"e664707_4-vitt.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001067/e664707_4-vitt.xml","form_type":"4"}},{"id":1084609,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34787,"kind":"person","name":"Vitt Daniel","position":1,"cik":"0001773673","reported_name":"Vitt Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:05:56.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":1720000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":1720000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":1720000},"source":{"system":"sec-edgar","filing":"0001193805-25-001067","document":"e664707_4-vitt.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001067/e664707_4-vitt.xml","form_type":"4"}},{"id":1084608,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34787,"kind":"person","name":"Vitt Daniel","position":1,"cik":"0001773673","reported_name":"Vitt Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:05:56.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":1720000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":1720000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":1720000},"source":{"system":"sec-edgar","filing":"0001193805-25-001067","document":"e664707_4-vitt.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001067/e664707_4-vitt.xml","form_type":"4"}},{"id":1084607,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34787,"kind":"person","name":"Vitt Daniel","position":1,"cik":"0001773673","reported_name":"Vitt Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:05:56.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":860000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":860000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":860000},"source":{"system":"sec-edgar","filing":"0001193805-25-001067","document":"e664707_4-vitt.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001067/e664707_4-vitt.xml","form_type":"4"}},{"id":1084606,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:05:25.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":330000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001193805-25-001065","document":"e664705_4-jason.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001065/e664705_4-jason.xml","form_type":"4"}},{"id":1084605,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:05:25.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the \"January 2024 Offering\")."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":330000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001193805-25-001065","document":"e664705_4-jason.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001065/e664705_4-jason.xml","form_type":"4"}},{"id":1084604,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:05:25.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":660000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":660000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":660000},"source":{"system":"sec-edgar","filing":"0001193805-25-001065","document":"e664705_4-jason.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001065/e664705_4-jason.xml","form_type":"4"}},{"id":1084603,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:05:25.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":660000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":660000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":660000},"source":{"system":"sec-edgar","filing":"0001193805-25-001065","document":"e664705_4-jason.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001065/e664705_4-jason.xml","form_type":"4"}},{"id":1084602,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T20:05:25.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":330000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001193805-25-001065","document":"e664705_4-jason.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525001065/e664705_4-jason.xml","form_type":"4"}},{"id":1084767,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77371,"kind":"person","name":"Muehler Andreas","position":1,"cik":"0001850468","reported_name":"Muehler Andreas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T16:05:42.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the third tranche of the January 2024 Offering."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":330000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001193805-25-001066","document":"e664706_4-muehler.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1850468/000119380525001066/e664706_4-muehler.xml","form_type":"4"}},{"id":1084766,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77371,"kind":"person","name":"Muehler Andreas","position":1,"cik":"0001850468","reported_name":"Muehler Andreas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T16:05:42.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Exercisable beginning August 1, 2026, subject to the Issuer's issuance of Common Stock or pre-funded warrants to subscribers in connection with the second tranche of the Issuer's January 4, 2024 private placement (the \"January 2024 Offering\")."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":330000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001193805-25-001066","document":"e664706_4-muehler.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1850468/000119380525001066/e664706_4-muehler.xml","form_type":"4"}},{"id":1084765,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77371,"kind":"person","name":"Muehler Andreas","position":1,"cik":"0001850468","reported_name":"Muehler Andreas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T16:05:42.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":660000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series B purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":660000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":660000},"source":{"system":"sec-edgar","filing":"0001193805-25-001066","document":"e664706_4-muehler.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1850468/000119380525001066/e664706_4-muehler.xml","form_type":"4"}},{"id":1084764,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77371,"kind":"person","name":"Muehler Andreas","position":1,"cik":"0001850468","reported_name":"Muehler Andreas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T16:05:42.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":660000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Exercisable beginning August 1, 2026, subject to the exercise of the Issuer's series A purchase warrants by the holders thereof."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":660000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":660000},"source":{"system":"sec-edgar","filing":"0001193805-25-001066","document":"e664706_4-muehler.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850468/000119380525001066/e664706_4-muehler.xml","form_type":"4"}},{"id":1084763,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77371,"kind":"person","name":"Muehler Andreas","position":1,"cik":"0001850468","reported_name":"Muehler Andreas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Appreciation Right","published_at":"2025-07-18T16:05:42.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":330000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Stock Appreciation Rights (\"SARs\") could be settled for cash, but it is the intention of the Issuer that these SARs will be settled for shares of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\") provided the Issuer obtains stockholder approval to amend the Issuer's 2019 Omnibus Equity Incentive Plan, as amended, to provide for a sufficient number of shares of Common Stock to support the settlement of the SARs in shares of Common Stock."}],"balance_after":330000,"derivative":{"exercise_price":0.77,"exercise_date":"2026-08-01","expiration_date":"2035-07-16","underlying":"Common Stock","underlying_shares":330000},"source":{"system":"sec-edgar","filing":"0001193805-25-001066","document":"e664706_4-muehler.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850468/000119380525001066/e664706_4-muehler.xml","form_type":"4"}},{"id":1104858,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option","published_at":"2025-06-20T21:16:19.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":598500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":598500,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":598500},"source":{"system":"sec-edgar","filing":"0001193805-25-000925","document":"e664640_4a-jason.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000925/e664640_4a-jason.xml","form_type":"4/A","original_submission_date":"2025-06-09"}},{"id":1104857,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2025-06-20T21:16:19.000Z","date":"2025-06-05","kind":"purchase","planned":false,"acquired":true,"shares":12512,"price":0.79,"value":9884.48,"ownership":{"direct":true},"balance_after":12512,"source":{"system":"sec-edgar","filing":"0001193805-25-000925","document":"e664640_4a-jason.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000925/e664640_4a-jason.xml","form_type":"4/A","original_submission_date":"2025-06-09"}},{"id":1104856,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34788,"kind":"person","name":"Whaley Glenn","position":1,"cik":"0001724623","reported_name":"Whaley Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2025-06-20T21:16:01.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":503500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":503500,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":503500},"source":{"system":"sec-edgar","filing":"0001193805-25-000924","document":"e664639_4a-whaley.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000924/e664639_4a-whaley.xml","form_type":"4/A","original_submission_date":"2025-06-09"}},{"id":1104855,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34787,"kind":"person","name":"Vitt Daniel","position":1,"cik":"0001773673","reported_name":"Vitt Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Option","published_at":"2025-06-20T21:15:45.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":1558000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":1558000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":1558000},"source":{"system":"sec-edgar","filing":"0001193805-25-000923","document":"e664638_4a-vitt.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000923/e664638_4a-vitt.xml","form_type":"4/A","original_submission_date":"2025-06-06"}},{"id":1104854,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34787,"kind":"person","name":"Vitt Daniel","position":1,"cik":"0001773673","reported_name":"Vitt Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Common Stock","published_at":"2025-06-20T21:15:45.000Z","date":"2025-06-04","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.77,"value":11550.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase was made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 4, 2025 (at Euro 1.00 = U.S. dollar 1.1384)."}],"balance_after":29000,"source":{"system":"sec-edgar","filing":"0001193805-25-000923","document":"e664638_4a-vitt.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000923/e664638_4a-vitt.xml","form_type":"4/A","original_submission_date":"2025-06-06"}},{"id":1104853,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2025-06-20T21:15:28.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":570000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":570000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":570000},"source":{"system":"sec-edgar","filing":"0001193805-25-000922","document":"e664637_4a-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000922/e664637_4a-duane.xml","form_type":"4/A","original_submission_date":"2025-06-09"}},{"id":1105115,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77371,"kind":"person","name":"Muehler Andreas","position":1,"cik":"0001850468","reported_name":"Muehler Andreas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2025-06-20T17:15:10.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":598500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":598500,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":598500},"source":{"system":"sec-edgar","filing":"0001193805-25-000921","document":"e664636_4a-muehler.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850468/000119380525000921/e664636_4a-muehler.xml","form_type":"4/A","original_submission_date":"2025-06-09"}},{"id":1109659,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-06-16T21:00:19.000Z","date":"2025-06-13","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.8347,"value":16694.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.83 to $0.84. The Reporting Person (RP) undertakes to provide to the Issuer, any securityholder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price."}],"balance_after":36032,"source":{"system":"sec-edgar","filing":"0001193805-25-000885","document":"e664632_4-duane.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000885/e664632_4-duane.xml","form_type":"4"}},{"id":1117693,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":17364,"kind":"person","name":"HOWSON TAMAR D","position":1,"cik":"0001202286","reported_name":"HOWSON TAMAR D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-09T20:09:04.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":150000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193805-25-000843","document":"e664612_4-howson.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000843/e664612_4-howson.xml","form_type":"4"}},{"id":1118293,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31759,"kind":"person","name":"Skerjanec Simona","position":1,"cik":"0002022163","reported_name":"Skerjanec Simona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-09T20:08:41.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":150000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193805-25-000842","document":"e664611_4-skerjanec.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022163/000119380525000842/e664611_4-skerjanec.xml","form_type":"4"}},{"id":1117692,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31661,"kind":"person","name":"Rudick Richard Alan","position":1,"cik":"0001975263","reported_name":"Rudick Richard Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-09T20:08:14.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":150000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193805-25-000841","document":"e664610_4-rudick.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000841/e664610_4-rudick.xml","form_type":"4"}},{"id":1117691,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option","published_at":"2025-06-09T20:07:31.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":595000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":595000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":595000},"source":{"system":"sec-edgar","filing":"0001193805-25-000839","document":"e664608_4-jason.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000839/e664608_4-jason.xml","form_type":"4"}},{"id":1117690,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Common Stock","published_at":"2025-06-09T20:07:31.000Z","date":"2025-06-05","kind":"purchase","planned":false,"acquired":true,"shares":12512,"price":0.79,"value":9884.48,"ownership":{"direct":true},"balance_after":12512,"source":{"system":"sec-edgar","filing":"0001193805-25-000839","document":"e664608_4-jason.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000839/e664608_4-jason.xml","form_type":"4"}},{"id":1117689,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31659,"kind":"person","name":"Neermann Joerg","position":1,"cik":"0001773900","reported_name":"Neermann Joerg","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-09T20:07:05.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":150000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193805-25-000838","document":"e664607_4-jorg.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000838/e664607_4-jorg.xml","form_type":"4"}},{"id":1117687,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34788,"kind":"person","name":"Whaley Glenn","position":1,"cik":"0001724623","reported_name":"Whaley Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2025-06-09T20:06:41.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":503000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":503000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":503000},"source":{"system":"sec-edgar","filing":"0001193805-25-000837","document":"e664606_4-whaley.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000837/e664606_4-whaley.xml","form_type":"4"}},{"id":1117688,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2025-06-09T20:06:06.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":560000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":560000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":560000},"source":{"system":"sec-edgar","filing":"0001193805-25-000836","document":"e664604_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000836/e664604_4-duane.xml","form_type":"4"}},{"id":1117686,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31660,"kind":"person","name":"PHILLIPS BARCLAY A","position":1,"cik":"0001265801","reported_name":"PHILLIPS BARCLAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-09T20:05:42.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":150000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193805-25-000835","document":"e664603_4-phillips.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000835/e664603_4-phillips.xml","form_type":"4"}},{"id":1118141,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":78736,"kind":"person","name":"Toernsen Monika Maria","position":1,"cik":"0001873385","reported_name":"Toernsen Monika Maria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-09T16:07:46.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":150000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001193805-25-000840","document":"e664609_4-toernsen.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873385/000119380525000840/e664609_4-toernsen.xml","form_type":"4"}},{"id":1118092,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77371,"kind":"person","name":"Muehler Andreas","position":1,"cik":"0001850468","reported_name":"Muehler Andreas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2025-06-09T16:05:31.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":595000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":595000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":595000},"source":{"system":"sec-edgar","filing":"0001193805-25-000834","document":"e664602_4-muehler.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850468/000119380525000834/e664602_4-muehler.xml","form_type":"4"}},{"id":1119409,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34787,"kind":"person","name":"Vitt Daniel","position":1,"cik":"0001773673","reported_name":"Vitt Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Option","published_at":"2025-06-06T21:00:54.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":1535000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":1535000,"derivative":{"exercise_price":0.7729,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":1535000},"source":{"system":"sec-edgar","filing":"0001193805-25-000821","document":"e664605_4-vitt.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000821/e664605_4-vitt.xml","form_type":"4"}},{"id":1119408,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34787,"kind":"person","name":"Vitt Daniel","position":1,"cik":"0001773673","reported_name":"Vitt Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Common Stock","published_at":"2025-06-06T21:00:54.000Z","date":"2025-06-04","kind":"purchase","planned":false,"acquired":true,"shares":15000,"price":0.77,"value":11550.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase was made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 4, 2025 (at Euro 1.00 = U.S. dollar 1.1384)."}],"balance_after":29000,"source":{"system":"sec-edgar","filing":"0001193805-25-000821","document":"e664605_4-vitt.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000821/e664605_4-vitt.xml","form_type":"4"}},{"id":1121104,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31659,"kind":"person","name":"Neermann Joerg","position":1,"cik":"0001773900","reported_name":"Neermann Joerg","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:07:04.000Z","date":"2025-06-05","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":0.76,"value":22800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The purchase was made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 5, 2025 (at Euro 1.00 = U.S. dollar 1.1477)."}],"balance_after":200000,"source":{"system":"sec-edgar","filing":"0001193805-25-000800","document":"e664594_4-jorg.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000800/e664594_4-jorg.xml","form_type":"4"}},{"id":1121103,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31659,"kind":"person","name":"Neermann Joerg","position":1,"cik":"0001773900","reported_name":"Neermann Joerg","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-05T20:07:04.000Z","date":"2025-06-04","kind":"purchase","planned":false,"acquired":true,"shares":70000,"price":0.77,"value":53900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7661 to $0.7730. The Reporting Person (RP) undertakes to provide to the Issuer, any securityholder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The purchases were made in Euros and the price was converted into U.S. dollars based on the foreign currency exchange rate as of June 4, 2025 (at Euro 1.00 = U.S. dollar 1.1384)."}],"balance_after":170000,"source":{"system":"sec-edgar","filing":"0001193805-25-000800","document":"e664594_4-jorg.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000800/e664594_4-jorg.xml","form_type":"4"}},{"id":1122655,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34788,"kind":"person","name":"Whaley Glenn","position":1,"cik":"0001724623","reported_name":"Whaley Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-04T20:22:22.000Z","date":"2025-06-03","kind":"purchase","planned":false,"acquired":true,"shares":45000,"price":0.7128,"value":32076.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7127 to $0.7134. The RP undertakes to provide to the Issuer, any securityholder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price."}],"balance_after":95510,"source":{"system":"sec-edgar","filing":"0001193805-25-000788","document":"e664584_4-whaley.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000788/e664584_4-whaley.xml","form_type":"4"}},{"id":1122654,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34788,"kind":"person","name":"Whaley Glenn","position":1,"cik":"0001724623","reported_name":"Whaley Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-06-04T20:22:22.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0.56,"value":14000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The Reporting Person (RP) is voluntarily reporting the acquisition of shares of common stock pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) in a transaction exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the Issuer's common stock on May 30, 2025."}],"balance_after":50510,"source":{"system":"sec-edgar","filing":"0001193805-25-000788","document":"e664584_4-whaley.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000788/e664584_4-whaley.xml","form_type":"4"}},{"id":1122653,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31661,"kind":"person","name":"Rudick Richard Alan","position":1,"cik":"0001975263","reported_name":"Rudick Richard Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-04T20:06:00.000Z","date":"2025-06-03","kind":"purchase","planned":false,"acquired":true,"shares":143075,"price":0.6991,"value":100023.7325,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6955 to $0.6993. The Reporting Person (RP) undertakes to provide to the Issuer, any securityholder of the Issuer, or the SEC staff, upon request, information regarding the number of shares purchased at each price."}],"balance_after":230375,"source":{"system":"sec-edgar","filing":"0001193805-25-000786","document":"e664585_4-rudick.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380525000786/e664585_4-rudick.xml","form_type":"4"}},{"id":1338840,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-12-09T13:30:26.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":300000,"derivative":{"exercise_price":1.25,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193805-24-001448","document":"e664066_4a-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001448/e664066_4a-duane.xml","form_type":"4/A","original_submission_date":"2024-12-06"}},{"id":1340266,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-12-06T22:32:07.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":300000,"derivative":{"exercise_price":1.25,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193805-24-001444","document":"e664062_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001444/e664062_4-duane.xml","form_type":"4"}},{"id":1340267,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option","published_at":"2024-12-06T22:31:19.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":157500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":157500,"derivative":{"exercise_price":1.25,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":157500},"source":{"system":"sec-edgar","filing":"0001193805-24-001442","document":"e664060_4-jason.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001442/e664060_4-jason.xml","form_type":"4"}},{"id":1340265,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34787,"kind":"person","name":"Vitt Daniel","position":1,"cik":"0001773673","reported_name":"Vitt Daniel","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO and Director"}}],"security":"Stock Option","published_at":"2024-12-06T22:30:55.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":820000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":820000,"derivative":{"exercise_price":1.25,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":820000},"source":{"system":"sec-edgar","filing":"0001193805-24-001441","document":"e664059_4-vitt.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001441/e664059_4-vitt.xml","form_type":"4"}},{"id":1340264,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34788,"kind":"person","name":"Whaley Glenn","position":1,"cik":"0001724623","reported_name":"Whaley Glenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option","published_at":"2024-12-06T22:30:22.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":265000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":265000,"derivative":{"exercise_price":1.25,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":265000},"source":{"system":"sec-edgar","filing":"0001193805-24-001440","document":"e664058_4-whaley.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001440/e664058_4-whaley.xml","form_type":"4"}},{"id":1340587,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77371,"kind":"person","name":"Muehler Andreas","position":1,"cik":"0001850468","reported_name":"Muehler Andreas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option","published_at":"2024-12-06T17:31:44.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":315000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months."}],"balance_after":315000,"derivative":{"exercise_price":1.25,"expiration_date":"2034-12-04","underlying":"Common Stock","underlying_shares":315000},"source":{"system":"sec-edgar","filing":"0001193805-24-001443","document":"e664061_4-muehler.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850468/000119380524001443/e664061_4-muehler.xml","form_type":"4"}},{"id":1366401,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31661,"kind":"person","name":"Rudick Richard Alan","position":1,"cik":"0001975263","reported_name":"Rudick Richard Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T19:13:22.000Z","date":"2024-11-12","kind":"purchase","planned":false,"acquired":true,"shares":87300,"price":1.1497,"value":100368.81,"ownership":{"direct":true},"balance_after":87300,"source":{"system":"sec-edgar","filing":"0001193805-24-001335","document":"e664024_4-rudick.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524001335/e664024_4-rudick.xml","form_type":"4"}},{"id":1449494,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31759,"kind":"person","name":"Skerjanec Simona","position":1,"cik":"0002022163","reported_name":"Skerjanec Simona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-07-24T20:11:28.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Additionally, in respect of such appointment, Reporting Person received from Immunic, Inc. a grant of options to purchase up to 50,000 shares of Immunic, Inc.'s common stock, which vest monthly over one year, effective July 22, 2024."}],"balance_after":50000,"derivative":{"exercise_price":1.46,"expiration_date":"2034-07-22","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193805-24-000961","document":"e663799_4-skerjanec.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022163/000119380524000961/e663799_4-skerjanec.xml","form_type":"4"}},{"id":1449493,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31759,"kind":"person","name":"Skerjanec Simona","position":1,"cik":"0002022163","reported_name":"Skerjanec Simona","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-07-24T20:11:28.000Z","date":"2024-07-22","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In relation to Reporting Person's directorship appointment at Immunic, Inc., Reporting Person received an inducement grant of options to purchase up to 100,000 shares of Immunic, Inc.'s common stock, which vest monthly over three years, effective July 22, 2024."}],"balance_after":100000,"derivative":{"exercise_price":1.46,"expiration_date":"2034-07-22","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193805-24-000961","document":"e663799_4-skerjanec.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022163/000119380524000961/e663799_4-skerjanec.xml","form_type":"4"}},{"id":1455234,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":34789,"kind":"person","name":"Tardio Jason","position":1,"cik":"0001794698","reported_name":"Tardio Jason","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and COO"}}],"security":"Stock Option","published_at":"2024-07-12T12:31:36.000Z","date":"2024-07-12","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options disclosed on this Form 4 are time vested; 25 percent of the shares underlying the options awarded to the Reporting Person will vest on July 12, 2025, and 75 percent of them will vest in 36 equal monthly installments, subject to the Reporting Person remaining an employee of Immunic, Inc. in good standing through the relevant vesting date."}],"balance_after":500000,"derivative":{"exercise_price":1.25,"expiration_date":"2034-07-12","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001193805-24-000914","document":"e663770_4-jason.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000914/e663770_4-jason.xml","form_type":"4"}},{"id":1481906,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31659,"kind":"person","name":"Neermann Joerg","position":1,"cik":"0001773900","reported_name":"Neermann Joerg","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-06-12T20:08:53.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":100000,"derivative":{"exercise_price":1.27,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193805-24-000788","document":"e663707_4-jorg.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000788/e663707_4-jorg.xml","form_type":"4"}},{"id":1481905,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31660,"kind":"person","name":"PHILLIPS BARCLAY A","position":1,"cik":"0001265801","reported_name":"PHILLIPS BARCLAY A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-06-12T20:08:10.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":100000,"derivative":{"exercise_price":1.27,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193805-24-000787","document":"e663706_4-phillips.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000787/e663706_4-phillips.xml","form_type":"4"}},{"id":1481904,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":31661,"kind":"person","name":"Rudick Richard Alan","position":1,"cik":"0001975263","reported_name":"Rudick Richard Alan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-06-12T20:07:19.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":100000,"derivative":{"exercise_price":1.27,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193805-24-000786","document":"e663705_4-rudick.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000786/e663705_4-rudick.xml","form_type":"4"}},{"id":1481903,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":17364,"kind":"person","name":"HOWSON TAMAR D","position":1,"cik":"0001202286","reported_name":"HOWSON TAMAR D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-06-12T20:05:19.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":100000,"derivative":{"exercise_price":1.27,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193805-24-000784","document":"e663703_4-howson.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000784/e663703_4-howson.xml","form_type":"4"}},{"id":1482274,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":78736,"kind":"person","name":"Toernsen Monika Maria","position":1,"cik":"0001873385","reported_name":"Toernsen Monika Maria","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-06-12T16:05:58.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly increments over a period of one year from the grant date."}],"balance_after":100000,"derivative":{"exercise_price":1.27,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193805-24-000785","document":"e663704_4-toernsen.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1873385/000119380524000785/e663704_4-toernsen.xml","form_type":"4"}},{"id":1591221,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":17364,"kind":"person","name":"HOWSON TAMAR D","position":1,"cik":"0001202286","reported_name":"HOWSON TAMAR D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-03-07T02:52:18.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":64959,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":64959,"derivative":{"exercise_price":1.72,"underlying":"Common Stock","underlying_shares":64959},"source":{"system":"sec-edgar","filing":"0001193805-24-000325","document":"e619339_4-howson.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000325/e619339_4-howson.xml","form_type":"4"}},{"id":1591220,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":17364,"kind":"person","name":"HOWSON TAMAR D","position":1,"cik":"0001202286","reported_name":"HOWSON TAMAR D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-03-07T02:52:18.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":3.4,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193805-24-000325","document":"e619339_4-howson.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000325/e619339_4-howson.xml","form_type":"4"}},{"id":1591219,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":17364,"kind":"person","name":"HOWSON TAMAR D","position":1,"cik":"0001202286","reported_name":"HOWSON TAMAR D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-03-07T02:52:18.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":14.77,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193805-24-000325","document":"e619339_4-howson.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000325/e619339_4-howson.xml","form_type":"4"}},{"id":1591218,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":17364,"kind":"person","name":"HOWSON TAMAR D","position":1,"cik":"0001202286","reported_name":"HOWSON TAMAR D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-03-07T02:52:18.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":12.3,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193805-24-000325","document":"e619339_4-howson.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000325/e619339_4-howson.xml","form_type":"4"}},{"id":1591217,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":17364,"kind":"person","name":"HOWSON TAMAR D","position":1,"cik":"0001202286","reported_name":"HOWSON TAMAR D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-03-07T02:52:18.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9986,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":9.54,"expiration_date":"2029-10-11","underlying":"Common Stock","underlying_shares":9986},"source":{"system":"sec-edgar","filing":"0001193805-24-000325","document":"e619339_4-howson.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000325/e619339_4-howson.xml","form_type":"4"}},{"id":1591216,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":17364,"kind":"person","name":"HOWSON TAMAR D","position":1,"cik":"0001202286","reported_name":"HOWSON TAMAR D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2024-03-07T02:52:18.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19973,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":9.54,"expiration_date":"2029-10-11","underlying":"Common Stock","underlying_shares":19973},"source":{"system":"sec-edgar","filing":"0001193805-24-000325","document":"e619339_4-howson.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000325/e619339_4-howson.xml","form_type":"4"}},{"id":1591215,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"grant","planned":false,"acquired":true,"shares":379959,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":379959,"derivative":{"exercise_price":1.72,"underlying":"Common Stock","underlying_shares":379959},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591214,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":3.4,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591213,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":10.88,"expiration_date":"2032-03-10","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591212,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":14.77,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591211,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":15.44,"expiration_date":"2031-04-15","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591210,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":120000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2030-10-22","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591209,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":12.3,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591208,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":12.3,"expiration_date":"2030-07-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}},{"id":1591207,"issuer":{"id":6306,"kind":"organization","name":"IMMUNIC, INC."},"owners":[{"id":77369,"kind":"person","name":"Nash Duane","position":1,"cik":"0001591098","reported_name":"Nash Duane","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option","published_at":"2024-03-07T02:52:02.000Z","date":"2024-03-04","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19973,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the \"Eligible Options\") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date."}],"balance_after":0,"derivative":{"exercise_price":13.63,"expiration_date":"2029-07-22","underlying":"Common Stock","underlying_shares":19973},"source":{"system":"sec-edgar","filing":"0001193805-24-000324","document":"e619338_4-duane.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280776/000119380524000324/e619338_4-duane.xml","form_type":"4"}}],"next_cursor":"2024-03-07T02:52:02.000000Z,1591207"}